Format

Send to

Choose Destination
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S21-35. doi: 10.1177/1758834011422557.

c-MET as a potential therapeutic target and biomarker in cancer.

Author information

1
Princess Margaret Hospital/Ontario Cancer Institute and University of Toronto, Toronto, Ontario, Canada.

Abstract

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This review provides an overview of the evidence to support c-MET or the HGF/c-MET signaling pathway as relevant targets for personalized cancer treatment based on high frequencies of c-MET and/or HGF overexpression, activation, amplification in non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colon and kidney carcinomas. Additionally, the current knowledge of small molecule inhibitors (tivantinib [ARQ 197]), c-MET/HGF antibodies (rilotumumab and MetMAb) and mechanisms of resistance to c-MET-targeted therapies are discussed.

KEYWORDS:

c-MET; cancer; hepatocyte growth factor; personalized medicine; targeted therapy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center